Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock News
CG Oncology, Inc. Common stock Quantitative Score
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CG Oncology, Inc. Common stock Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
CG Oncology, Inc. Common stock Financials
Table Compare
Compare CGON metrics with: | |||
|---|---|---|---|
Earnings & Growth | CGON | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CGON | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CGON | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CGON | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
CG Oncology, Inc. Common stock Income
CG Oncology, Inc. Common stock Balance Sheet
CG Oncology, Inc. Common stock Cash Flow
CG Oncology, Inc. Common stock Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
CG Oncology, Inc. Common stock Executives
| Name | Role |
|---|---|
| Mr. Arthur Kuan | Chairman & Chief Executive Officer |
| Mr. Ambaw Bellete M.S. | President & Chief Operating Officer |
| Ms. Corleen M. Roche | Chief Financial Officer |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Arthur Kuan | Chairman & Chief Executive Officer | Male | 1991 | 1.04M |
| Mr. Ambaw Bellete M.S. | President & Chief Operating Officer | Male | 1971 | 769.97K |
| Ms. Corleen M. Roche | Chief Financial Officer | Female | 1967 | 687.83K |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer | 1968 | 299.69K | |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy | Female | -- |
CG Oncology, Inc. Common stock Insider Trades
| Date | 21 May |
| Name | POST LEONARD E |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1000 |
| Date | 21 May |
| Name | POST LEONARD E |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1000 |
| Date | 21 May |
| Name | POST LEONARD E |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1000 |
| Date | 28 Apr |
| Name | POST LEONARD E |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1000 |
| Date | 28 Apr |
| Name | POST LEONARD E |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 May | POST LEONARD E | Director | Acquired | M-Exempt | 1000 |
| 21 May | POST LEONARD E | Director | Disposed | S-Sale | 1000 |
| 21 May | POST LEONARD E | Director | Disposed | M-Exempt | 1000 |
| 28 Apr | POST LEONARD E | Director | Disposed | S-Sale | 1000 |
| 28 Apr | POST LEONARD E | Director | Acquired | M-Exempt | 1000 |